Invigor Group set to put more money in the bank

|

Published 16-MAY-2016 12:09 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Invigor Group Limited (ASX:IVO) has signed a binding term sheet with IVS Holdings Limited (IVS) to vary its previous commercial arrangements and put more cash in the bank.

Invigor currently has a holding in My Verified ID Holdings Pty Ltd (MVID), a subsidiary of the IVS Group.

IVS and its subsidiaries have developed and patented technology that allows rapid, low cost, identity verification for online financial transactions.

Invigor previously announced that it had agreed to sell its interest in the IVS Group for $2m in cash and shares contingent on the completion of the capital raising by IVS under the prospectus.

Under the newly agreed terms, Invigor will now receive $500,000 when IVS completes a pre-IPO fundraising, which is expected to be completed within 90 days.

A further $500,000 will be distributed to IVO following completion of IVS’s IPO. The IPO is expected to be completed by 30 October 2016.

Invigor will be issued shared in IVS to the value of $1.2 million.

All up Invigor can expect $2.3 million to land in its bank account consisting of a $1.1 million cash component, 1.2 million shares and the $100,000 in cash that has already been paid.

The number of shares issued by IVS to IVO will be dependent on the IPO issue price. The shares will be held in voluntary escrow for three months from listing date and then released in blocks during the following nine months subject to ASX listing ruling requirements.

“We are pleased that we have agreed with IVS the news transactions terms to enable the holding in MVID to be fully realised in a way that brings value to all involved,” said Invigor CEO Gary Cohen.

“With the shareholding in IVS, we will be able to participate in upside from the eventual listing of IVS whilst also ensuring that Invigor has additional liquidity from receiving the $1.2 million in cash.”

The extra money will enable IVO to maintain its current momentum in strengthening its local and international foothold in the brand analytics solutions space.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X